FOXO TECHNOLOGIES INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
FOXO TECHNOLOGIES INC. (FOXO) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $2.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-14
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.57M.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $927.50K, a 287.30% increase year-over-year.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $743.12K, a 66.52% decline year-over-year.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$132.59K, a 143.78% decline year-over-year.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $635.41K, a 64.45% decline from fiscal 2024.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.79M, a 43.28% decline from fiscal 2023.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $3.15M, a 34.89% increase from fiscal 2022.
- FOXO TECHNOLOGIES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $2.34M, a 1416.88% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.50M 10-Q · filed 2026-08-14 | $3.24M derived: sum of 3 quarters · filed 2026-08-14 | $3.11M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $927.50K 10-Q · filed 2026-05-15 | $1.67M derived: sum of 2 quarters · filed 2026-05-15 | $1.54M derived: sum of 3 quarters · filed 2026-05-15 | $1.32M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $743.12K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $610.53K derived: sum of 2 quarters · filed 2026-04-15 | $395.93K derived: sum of 3 quarters · filed 2026-08-14 | $635.41K 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | -$132.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$347.18K derived: sum of 2 quarters · filed 2026-08-14 | -$107.71K 10-Q · filed 2025-11-10 | $2.11M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$214.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $24.88K 10-Q · filed 2026-08-14 | $2.24M derived: sum of 3 quarters · filed 2026-08-14 | $2.55M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $239.48K 10-Q · filed 2026-05-15 | $2.46M derived: sum of 2 quarters · filed 2026-05-15 | $2.76M derived: sum of 3 quarters · filed 2026-05-15 | $2.66M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $2.52M derived: sum of 2 quarters · filed 2026-04-15 | $2.42M derived: sum of 3 quarters · filed 2026-04-15 | $1.79M 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | $302.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $203.18K derived: sum of 2 quarters · filed 2025-11-10 | -$432.17K 10-Q · filed 2025-11-10 | -$432.00K 10-Q · filed 2024-11-19 | $827.96K derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | -$99.65K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2025-08-19 | -$735.00K 10-Q · filed 2025-08-19 | $1.00M 10-Q · filed 2024-08-19 | $525.13K derived: sum of 3 quarters · filed 2025-08-19 | $2.53M derived: sum of 4 quarters · filed 2025-08-19 | |||
| 2024-03-31 | -$635.34K 10-Q/A · filed 2025-08-19 | $1.49M 10-Q · filed 2024-06-28 | $624.78K derived: sum of 2 quarters · filed 2025-08-19 | $2.63M derived: sum of 3 quarters · filed 2025-08-19 | $2.48M derived: sum of 4 quarters · filed 2025-08-19 | |||
| 2023-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $3.27M derived: sum of 2 quarters · filed 2025-04-15 | $3.12M derived: sum of 3 quarters · filed 2025-04-15 | $3.15M 10-K · filed 2025-04-15 | $2.35M 10-K · filed 2024-06-06 | |||
| 2023-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | $1.86M derived: sum of 2 quarters · filed 2024-11-19 | $1.89M 10-Q · filed 2024-11-19 | $3.47M derived: sum of 4 quarters · filed 2024-11-19 | ||||
| 2023-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$116.00K 10-Q · filed 2024-08-19 | $1.46M derived: sum of 3 quarters · filed 2024-08-19 | $1.87M derived: sum of 4 quarters · filed 2024-08-19 | ||||
| 2023-03-31 | $35.00K 10-Q · filed 2024-06-28 | $1.61M derived: sum of 2 quarters · filed 2024-06-28 | $2.02M derived: sum of 3 quarters · filed 2024-06-28 | $2.22M derived: sum of 4 quarters · filed 2024-06-28 | ||||
| 2022-12-31 | $1.57M derived: 10-K 12 month − 10-Q/A 9 month · filed 2024-06-06 | $1.99M derived: sum of 2 quarters · filed 2024-06-06 | $2.19M derived: sum of 3 quarters · filed 2024-06-06 | $2.34M 10-K · filed 2024-06-06 | ||||
| 2022-09-30 | $411.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2024-06-04 | $612.00K derived: sum of 2 quarters · filed 2024-06-04 | $761.00K 10-Q/A · filed 2024-06-04 | $718.00K derived: sum of 4 quarters · filed 2024-06-04 | ||||
| 2022-06-30 | $201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $350.00K 10-Q · filed 2023-08-10 | $307.00K derived: sum of 3 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | $149.00K 10-Q · filed 2023-05-11 | $106.00K derived: sum of 2 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $154.00K 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | $197.00K 10-Q · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |